Adenosine A receptors promote collagen production by a Fli1- and CTGF-mediated mechanism by unknown
RESEARCH ARTICLE Open Access
Adenosine A2A receptors promote collagen
production by a Fli1- and CTGF-mediated
mechanism
Edwin SL Chan1*, Hailing Liu1, Patricia Fernandez1,2, Alex Luna1, Miguel Perez-Aso1, Andreea M Bujor3,
Maria Trojanowska3 and Bruce N Cronstein1
Abstract
Introduction: Adenosine, acting through the A2A receptor, promotes tissue matrix production in the skin and the
liver and induces the development of dermal fibrosis and cirrhosis in murine models. Since expression of A2A
receptors is increased in scleroderma fibroblasts, we examined the mechanisms by which the A2A receptor
produces its fibrogenic effects.
Methods: The effects of A2A receptor ligation on the expression of the transcription factor, Fli1, a constitutive
repressor for the synthesis of matrix proteins, such as collagen, is studied in dermal fibroblasts. Fli1 is also known
to repress the transcription of CTGF/CCN2, and the effects of A2A receptor stimulation on CTGF and TGF-b1
expression are also examined.
Results: A2A receptor occupancy suppresses the expression of Fli1 by dermal fibroblasts. A2A receptor activation
induces the secretion of CTGF by dermal fibroblasts, and neutralization of CTGF abrogates the A2A receptor-
mediated enhancement of collagen type I production. A2AR activation, however, resulted in a decrease in TGF-b1
protein release.
Conclusions: Our results suggest that Fli1 and CTGF are important mediators of the fibrogenic actions of
adenosine and the use of small molecules such as adenosine A2A receptor antagonists may be useful in the
therapy of dermal fibrosis in diseases such as scleroderma.
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Introduction
Matrix production is critical for wound healing and tis-
sue repair but in some clinical settings overproduction
of matrix provides the basis for organ injury and dys-
function [1]. In previous studies, we have demonstrated
that occupancy of adenosine A2A receptors by an appro-
priate agonist, such as CGS-21680, promotes more rapid
wound closure in both normal mice and diabetic rats
and the enhancement in dermal wound healing is
accompanied by an increase in matrix (collagen) in the
wounds [2-4]. We have recently shown that pharmaco-
logical A2AR blockade can be used to diminish scarring
while improving the collagen composition and tensile
strength of the healed wound [5]. Adenosine A2A recep-
tor agonists such as CGS21680 do not promote wound
healing in mice lacking adenosine A2A receptors and
these same A2A receptor-deficient mice are protected
from the development of hepatic and dermal fibrosis as
well [6,7]. Although exogenous adenosine receptor ago-
nists may promote wound healing, endogenous adeno-
sine production also contributes to wound healing and
pathologic fibrosis because mice lacking adenosine A2A
receptors have prolonged wound healing and mice that
underproduce adenosine in response to appropriate sti-
muli due to deletion of ecto-5’nucleotidase are protected
from the development of hepatic fibrosis [4,8]. Consis-
tent with the role of matrix overproduction in organ
fibrosis and dysfunction, we have further demonstrated
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that adenosine and its receptor play a critical role in
models of hepatic fibrosis/cirrhosis and dermal fibrosis
in a model of scleroderma [6,7,9] and others have
reported that adenosine plays a role in postoperative
abdominal adhesions [10].
Although adenosine and adenosine A2A receptors regu-
late the function of many cell types that stimulate matrix
production and fibrosis indirectly, we have reported that
stimulation of the A2A receptor on matrix producing fibro-
blasts in the skin and stellate cells in the liver directly sti-
mulates collagen production [6,7]. In a murine model
deficient for adenosine deaminase, a key catabolizing
enzyme for adenosine, we have shown that fibrosis devel-
oped spontaneously in the skin in the absence of exogen-
ous fibrogenic stimulators, concomitant with an increase
in adenosine levels in the skin [9]. In primary human der-
mal fibroblasts, the collagen-inducing effect of adenosine
can be attributed directly to A2A receptor occupancy,
since it is not attenuated by A1 receptor or A2B receptor
antagonism, and A3 receptors are not expressed on
human dermal fibroblasts [6]. Furthermore, A2A receptor-
deficient mice or mice treated with an A2A receptor
antagonist are protected against induction of fibrogenesis
in the skin by administration of bleomycin [6]. A2A recep-
tor antagonism also diminished dermal fibrogenesis in
adenosine deaminase-deficient mice [9]. Lazzerini et al.
have shown that expression of adenosine A2A receptors
are increased three-fold in dermal fibroblasts isolated from
scleroderma patients compared to non-diseased controls,
and A2A receptor ligation promotes collagen synthesis in
dermal fibroblasts [11]. The adenosine A2A receptor is a
GS-linked receptor that stimulates cAMP accumulation
and other downstream signals that mediate activation of
collagen production by fibroblasts and stellate cells. A
number of downstream signals play a role in the stimula-
tion of collagen production by stellate cells including acti-
vation of the downstream kinases ERK1/2 (linked to
collagen type I production) and p38 MAPKinase (linked to
collagen type III production) [12].
Matrix production depends on the balance between
forces that promote the transcription of matrix-produ-
cing genes and those that repress them. One of the best
characterized of such repressors to date is friend leuke-
mia integration-1 (Fli1), a member of the E26 transfor-
mation-specific (Ets) transcription factor family [13-16].
Reduction of Fli1 levels in dermal fibroblasts is associated
with increased synthesis of connective tissue growth fac-
tor (CTGF/CCN2) and type I collagen, as well as a reduc-
tion of MMP-1 production [15-19]. This bears much
similarity to the well known profibrotic effects of TGF-b.
Indeed, enforced expression of Fli1 almost entirely abro-
gated TGF-b-induced profibrotic gene expression [16],
suggesting that Fli1 is a potent endogenous antagonist of
TGF-b signaling. Asano and colleagues have recently
shown that TGF-b elicits PCAF-dependent acetylation of
Fli1, which in turn results in its dissociation from the
collagen promoter and subsequent degradation [20,21].
We therefore hypothesized that one of the possible
mechanisms for the fibrogenic effects of adenosine is
mediated through suppression of Fli1 expression.
Furthermore, since CTGF is a matrix-promoting growth
factor regulated by Fli1 and is vastly overexpressed in
adenosine deaminase-deficient mice [9,19], it may also be




CGS-21680 was purchased from Sigma (St. Louis, MO,
USA) and ZM-241385 was from Tocris (Ballwin, MO,
USA). Antibody for human Fli1 was from BD Biosciences
(San Jose, CA, USA), anti-CTGF and anti b-actin were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
anti-human p84 was from Abcam (Cambridge, MA, USA)
and anti-collagen I was purchased from Southern Biotech
(Birmingham, AL, USA). Anti-mouse and anti-rabbit
immunoglobulins were from DAKO (Carpinteria, CA,
USA). DMEM and cell culture reagents were from Invitro-
gen (Grand Island, NY, USA).
Cell culture
Primary adult human dermal fibroblasts were purchased
from Cambrex (East Rutherford, NJ, USA), or Lonza, Inc.
(Allendale, NJ, USA). Fibroblasts were cultured in DMEM
and used for experiments from first to the fifth passages.
For CTGF neutralization, the human dermal fibroblasts
where harvested during 16 hours and then incubated with
the CTGF antibody (1:250) or normal serum as a control.
Western blotting
To examine expression of Fli1 protein, nuclear extracts
from treated dermal fibroblasts were prepared following
manufacturer´s instructions (Active Motif Nuclear
Extract Protocol, Panomics, Fremont, CA, USA). Protein
concentration was measured by BCA method (Pierce,
Rockford, IL, USA) using bovine serum albumin as stan-
dard. Nuclear extracts (30 μg/lane) were electrophoresed
in 12.5% SDS-polyacrylamide gel and transferred onto a
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA).
The nitrocellulose membrane was blocked for two hours
at room temperature in blocking solution (3% non-fat
dry powdered milk in 1x Tween 20 Tris buffered saline
(TTBS consisting of 20 mM Tris-HCl, pH 7.4, 150 mM
NaCl and 0.1% Tween 20). After blocking, the membrane
was incubated with primary antibody Fli1 (1:500; BD
Pharmagen, San Jose, CA, USA), p84 (1:1,000; Abcam,
Cambridge, MA, USA) or b-Actin (1:1,000; Santa Cruz
Biotechnology Inc.,) overnight at 4ºC with gentle shaking
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on a platform shaker. After incubation with secondary
antibody (rabbit anti-mouse immunoglobulins, 1:1,000
dilution, one hour, room temperature), proteins were
visualized using the ECF kit (Amersham Biosciences, Lit-
tle Chalfont, Buckinghamshire, UK). Band intensities
were quantified by Adobe Photoshop 7.0.1 software and
normalized to p84 nuclear marker level. To examine the
expression of CTGF/CCN2, cells were plated 5x104/cm²
into six-well plates, starved overnight when cell number
reached 75% confluence and supernates were collected
following treatment. Samples were concentrated using
Microcon Ultracel YM-35 (Millipore, Billerica, MA,
USA), and concentrated supernates were electrophoresed
in a 10% SDS-polyacrylamide gel. CTGF/CCN2 was
detected with primary anti-CTGF/CCN2antibody
(1:1,000, Santa Cruz Biotechnology). Collagen type I was
assessed in cell lysates as previously described [6].
Reverse transcription and Real-time PCR
Total RNA from treated primary human dermal fibro-
blasts was isolated using Trizol (Invitrogen, Carlsbad, CA,
USA) following stimulation with CGS-21680 (10 μM)
according to the manufacturer’s protocol. RNA was quan-
tified using spectrophotometric OD260 measurements and
quality was assessed by OD260/ OD280 ratio. Reverse tran-
scription was performed using the GeneAmp RNA Core
Kit (Applied Biosystems, Carlsbad, CA, USA) in a volume
of 25 μl using oligo dT primers and MuLV reverse tran-
scriptase according to the manufacturer’s protocol. Real-
time PCRs were performed using the SYBR Green PCR
Master Mix (Stratagene, Santa Clara, CA, USA) following
the manufacturer’s instructions and carried out on the
Mx3005P™Q-PCR system (Stratagene). Aliquots of
reverse transcription reactions were subjected to PCR in
25 μl reactions with SYBR® green using primers for Fli1
[5’- caacacggaagtgctgttgt-3’ (forward), 5’-ccaaggggag-
gacttttgtt-3’ (reverse)], CTGF/CCN2 [5’-ttccagagcagctg-
caagta-3’ (forward), 5’-ctcgtcacacacccactcc-3’ (reverse),
GAPDH [5’-accatcatccctgcctctac-3’ (forward) and 5’-
cctgttgctgtagccaaat-3’ (reverse)], COL1A1 [5’-tgttcag-
ctttggacctccg-3’(forward), 5’-ccgttctgtacgcaggtgattg-3’
(reverse)], and COL3A1 [5’-gaagatgtccttgatgtgc-3’(for-
ward), 5’-agccttgcgtgttcgatat-3’(reverse)].
Primers were designed using output Primer 3 software
[22]. The thermal cycling conditions included an initial
95°C for 300 s; then 95°C for 60 s, 58°C for 45 s and 72°C
for 45 s for 40 cycles for Fli-1 and 95°C for 300 s; then
95°C for 60 s, 57°C for 45 s and 72°C for 45 s for 40
cycles for CTGF/CCN2. For each assay, standards, no-
template and no-RT controls were included to verify the
quality and cDNA specificity of the primers. Comparison
of the expression of each gene between its control and
stimulated states was determined with the delta-delta
(ΔΔ)Ct, according to the following formula: (ΔΔ)Ct =
((CtGOI Control - Ct HKG Control) - (CtGOI Stim - Ct HKG
Stim)), where GOI (gene of interest) corresponds to Fli1,
CTGF or COL1A1 and HKG (housekeeping gene) corre-
sponds to GAPDH. Fold increase was calculated accord-
ing to the formula: Fold = 2 (ΔΔ)Ct [23].
Determination of transforming growth factor -b1
Normal human dermal fibroblasts were serum starved for
24 h and stimulated with CGS-21680 (1μM). Then, trans-
forming growth factor b1 (TGF-b1) was determined in the
supernates after removing the debris by centrifugation
with the TGF-b1 ELISA kit (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s protocol.
Statistics
Results are represented as mean ± SEM. Data were ana-
lyzed by one-way ANOVA and significance of differences
between groups was determined by Newman-Keuls
method. Pairwise comparisons were made with the
unpaired t-test. All statistical analyses were performed
with Graphpad Prism software v. 4.02 (Graphpad Soft-
ware, La Jolla, CA, USA).
Results
Adenosine A2A receptor activation suppresses Fli1
expression in human dermal fibroblasts
We have previously demonstrated that adenosine A2A
receptor activation increases collagen production in der-
mal fibroblasts, including type I and III collagens [6],
although the molecular events involved are unclear. Since
suppression of Fli1 expression has also been associated
with increased collagen synthesis [16], we investigated
whether adenosine A2A receptor activation results in
alteration of Fli1 message expression. Following incubation
with the adenosine A2A agonist, CGS-21680, Fli1 mRNA
expression in dermal fibroblasts was reduced significantly
compared to control at four hours (56.8 ± 6.9%, n = 8,
P <0.05) (Figure 1A), but not at longer time-points (P =
NS). The effect of CGS-21680 on down-regulation of
Fli1 message was elicited with CGS-21680 (10 μM),
(Figure 1B). While the A2A receptor antagonist ZM241385
did not change the basal values for Fli1 mRNA, the impact
of CGS-21680 on Fli1 expression was significantly pre-
vented by coincubation with ZM241385 (1 μM, n = 8,
P <0.001 vs CGS) (Figure 1C). Similar to Fli1 message,
nuclear Fli1 protein expression in the nucleus was also sig-
nificantly suppressed by adenosine A2A receptor activation
compared to control (71.3 ± 6.3% of control, n = 3,
P <0.05), (Figure 2).
Adenosine A2A receptor activation promotes CTGF
secretion by dermal fibroblasts
We have previously reported that immunohistochemical
staining for CTGF (CCN2) is increased in adenosine
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Figure 1 Adenosine A2A receptor occupancy suppresses Fli1 mRNA expression in human dermal fibroblasts. NHDF cells were incubated
with CGS-26180 at A) 10 µM at the indicated time-points or B) 1 µM or 10 µM for four or eight hours. C) Incubation with the A2A receptor-
selective antagonist ZM241385 (1 µM) prior to CGS-26180 (10 µM) for four hours prevents the decrease on Fli1 expression. Data represent means
± S.E.M. of four to eight independent experiments. *P <0.05 vs. non-stimulated control (One-way ANOVA, post-hoc analysis by Newman-Keuls
test); ###P <0.001, CGS-26180 + ZM241385 vs. CGS-26180 (unpaired t-test).
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deaminase-deficient mice which have high tissue and
circulating adenosine levels compared to wild-type litter-
mate control mice [9] and therefore sought to determine
whether the effects of adenosine A2A receptor activation
on fibroblast function is associated with enhanced
CTGF production. Message for CTGF in dermal fibro-
blasts was increased to 1.47 ± 0.11-fold that of control
following treatment with the A2A receptor agonist, CGS-
21680 (n = 8, P <0.05 vs. control) (Figure 3A). The
CGS-21680-induced increase in CTGF was reversed by
pretreatment with the A2A antagonist ZM142385, while
ZM241385 alone did not alter CTGF mRNA expression.
While Fli1 nuclear protein expression was decreased,
CTGF protein levels in supernates (secreted CTGF) and
cell-associated CTGF (total lysate) in dermal fibroblast
cultures treated with CGS-21680 were also increased (to
160.3 ± 18.7% of control, secreted CTGF, n = 5, P <
0.05; and 127.0 ± 6.0% of control, total lysate, P = NS,
respectively) (Figure 3B).
CTGF is necessary for A2A receptor-mediated collagen
type I production
We have previously shown that adenosine A2A receptor
occupancy promotes collagen type I production at both
Figure 2 Adenosine A2A receptor occupancy inhibits nuclear Fli1 protein expression in human dermal fibroblasts. NHDF cells were
incubated with CGS-26180 at 1 to 10 µM over 24 hours and cellular fractionation was performed as described under “Methods”. A)
Representative Western-blot images showing Fli1 and the nuclear marker p84. B) Bands were quantified and data represent means ± S.E.M. from
three independent experiments. Statistics were performed by one-way ANOVA with post-hoc analysis by Newman-Keuls test, *P <0.05 vs. non-
stimulated control.
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Figure 3 Adenosine A2A receptor occupancy increases CTGF mRNA and protein expression and secretion. NHDF cells were incubated
with CGS-26180 at 1 µM A) for 4 hours for CTGF mRNA analysis or B) for 24 hours prior to cellular fractionation and protein concentration from
supernates as described under “Methods”. Bands were quantified and data represent means ± S.E.M. from three to eight independent
experiments. Statistics were performed by one-way ANOVA with post-hoc analysis by Newman-Keuls test, *P <0.05 vs. non-stimulated control.
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the message and protein levels [6]. Since A2A receptor
occupancy also enhanced CTGF secretion, we deter-
mined whether CTGF is a prerequisite for A2A receptor-
mediated collagen I production. We first investigated
the mRNA levels for COL1A1 (Figure 4A), and found a
significant increase following incubation with CGS-
21680 (1.47 ± 0.23-fold of control, n = 6, P <0.05). We
therefore sought to analyze the protein levels of collagen
I and, as previously demonstrated [6,12], we found that
CGS-21680 treatment increased collagen I protein by
50.1 ± 2.3% compared with control (n = 3, P <0.001)
(Figure 4B). However, the addition of a neutralizing
antibody to CTGF completely abrogated the CGS-
21680-induced increase in collagen I protein (101.7 ±
7.6% of control, n = 3, P <0.001 vs.CGS), but control
antiserum did not diminish the CGS21680-induced
increase (161.2 ± 3.3% of control, n = 3, P = NS). These
results suggest that increased secretion of CTGF is
involved in the A2A receptor-mediated collagen I
production.
A2AR activation prevents TGF-b1 release
It has been previously described that A2AR stimulation
increases the profibrogenic factor TGF-b1 at the mRNA
level in T cells [24]. Similarly, A2AR-deficient mice exhi-
bit highly decreased levels of TGF-b [25]. Since it is
well- known that TGF-b1 down-regulation of Fli1 pro-
motes fibrogenesis [20,26-28], to rule out the possibility
that the Fli1/ CTGF/ collagen pathway was induced via
up-regulation of TGF-b1 following CGS21680 incuba-
tion, we studied TGF-b1 release after A2AR activation.
As shown in Figure 5, released TGF-b1 was significantly
reduced following two-hour incubation with the A2AR
agonist, CGS21680. After 24 h, released TGF-b1 levels
were restored.
Discussion
We have previously shown that adenosine promotes
fibrogenesis in the skin in vivo [9], that A2AR blockade
prevents scarring in vivo [5] and activation of the adeno-
sine A2A receptor but not A1 or A2B receptors promotes
dermal extracellular matrix protein production including
type I collagen in primary human dermal fibroblasts,
and in a murine model of scleroderma [6]. Others have
shown that adenosine A2A receptor ligation increases
collagen production and induces a pro-fibrotic pheno-
type in dermal fibroblasts isolated from scleroderma
patients, in part by activation of the CB1 cannabinoid
receptor [11].The present study strongly suggests, for
the first time to our knowledge that an important
mechanism for the adenosine-mediated promotion of
fibrogenesis occurs at least in part through the regula-
tion of the Ets factor, Fli1, and connective tissue growth
factor (CTGF; CCN2). The importance of Fli1 in the
regulatory mechanism involved in the transcriptional
control of collagen gene expression has been well-
described. Characterization of the COL1A2 promoter
has identified a critical Ets-binding site mediating Fli1
inhibition [15]. In fact, Fli1 has been previously
described to function as a key regulator of the collagen
homeostasis in the skin in vivo by repressing the col-
lagen genes COL1A1, COL1A2, COL3A1, COL5A1 and
COL5A2 [21] and has also been shown to be signifi-
cantly reduced in clinically involved skin of patients
with scleroderma [16]. Other studies have shown that
inhibition of Fli1 by TGF-b and the subsequent displa-
cement of Fli1 from the CTGF promoter results in the
up-regulation of CTGF and the COL1A1 and COL1A2
genes in human dermal fibroblasts, strongly suggesting
that TGF-b-mediated Fli1 suppression is involved in the
activation of the profibrogenic gene program in fibro-
blasts [19]. In this regard, the secreted protein CTGF
[29,30] is a major mediator of the profibrotic effects of
TGF-b [19] and an important mediator of fibrosis since
its constitutive expression in fibroblasts is sufficient to
promote fibrotic disease in vivo [31].
Transforming growth factor (TGF-b) is known to be a
critical regulator of matrix synthesis [26-28], and Fli1 is
phosphorylated and acetylated following TGF-b1 treat-
ment in dermal fibroblasts [21,26-28]. On the other
hand, acetylation of Fli1 by TGF-b1 renders the Fli1
protein less stable, providing an important mechanism
for the pro-fibrotic actions of TGF-b1 [20,26-28]. Pre-
vious reports suggest a link between dysregulation of
Fli1 protein and scleroderma. Fli1 protein is markedly
down-regulated in lesional fibroblasts from scleroderma
patients [16]. Epigenetic mechanisms may also be
responsible, in part, for the repression of Fli1 gene in
scleroderma in vivo and increased methylation of the
Fli1 promoter region has been demonstrated in SSc
fibroblasts and skin biopsies from SSc patients [32]. Our
prior work indicates that adenosine and the A2A recep-
tor play a role in fibrosis in models of scleroderma.
Mice lacking the A2A receptor are protected from devel-
opment of dermal fibrosis following bleomycin exposure
and A2A receptor activation promotes collagen type I
and III production [12]. We, therefore, sought to analyze
if the A2A receptor regulates collagen production via
Fli1 and CTGF pathways.
Our present studies have shown that adenosine A2A
receptor activation in human dermal fibroblasts with the
agonist CGS-21680 promotes a reduction of Fli1 mRNA
and protein expression in the nucleus, as well as
increases in CTGF mRNA and protein expression and
secretion. These findings are consistent with previous
observations that Fli1 directly inhibits CTGF expression,
and knockdown of Fli1 dramatically up-regulates CTGF
in dermal fibroblasts [19]. Furthermore A2A receptor
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Figure 4 CTGF is involved in the A2A receptor-mediated collagen production. NHDF cells were incubated with CGS-26180 at 1 µM over A)
4 h for COL1A1 mRNA analysis or B) during 24 h for Western-blotting after 16 h-starvation. Where indicated, the neutralizing antibody to CTGF
(Ab; 1:250) or the A2AR antagonist ZM241385 (10 µM) was added prior to incubation with CGS-21680. Bands were quantified and data represent
means ± S.E.M. from three to six independent experiments. Statistics were performed by one-way ANOVA with post-hoc analysis by Newman-
Keuls test, ***P <0.001 CGS-26180 vs. non-stimulated control; ###P <0.001 CGS-26180 vs. CGS-26180 + CTGF Ab; and NS = non-significant, CGS-
26180 vs. CGS-26180 + Normal Serum.
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activation promotes an increase in collagen type I pro-
duction which is prevented by CTGF neutralization
(Figure 4B). This strongly suggests that Fli1 down-regu-
lation and CTGF up-regulation precede collagen induc-
tion upon A2AR activation. Interestingly, release of TGF-
b1 was reduced by A2AR activation. Our results there-
fore raise the possibility that A2AR and TGF-b1 may
prevent excessive fibrosis by compensating its redundant
pro-fibrogenic effects.
Recently, it has been suggested that hypoxia promotes
fibrogenesis [33,34]. In particular, hypoxia up-regulates
CTGF expression through activation of HIF-1a in der-
mal fibroblasts from scleroderma patients, and thereby
contributes to the progression of skin fibrosis [35]. In
this respect, as a critical mediator during hypoxia, the
actions of adenosine are potentiated by HIF, which has
been shown to stimulate the production of extracellular
adenosine [36,37], and suppresses both adenosine
uptake into the intracellular compartment and its intra-
cellular metabolism [36,38,39] (reviewed in [40]). In fact,
although HIF-1a has been shown to up-regulate A2BR
during conditions of hypoxia [39] suggesting a role for
Figure 5 TGF-b1 secretion is decreased by A2AR activation at earlier time points and restored after 24 hours. NHDF cells were serum-
starved and incubated with CGS-26180 1 µM at the indicated time periods and released TGF-b1 levels were analyzed by ELISA. Data represent
means ± S.E.M. from four independent experiments. Statistics were performed by unpaired-t test, ***P <0.001, **P <0.01, vs. non-stimulated
control.
Figure 6 Schema depicting the contribution of the Fli1 and CTGF pathways on the A2A receptor-mediated increase in collagen
production.
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the A2BR in tissue protection [41][42], the A2AR may
likely contribute to the role of adenosine in ischemic
settings [39,42]. Therefore, further studies will be
needed to fully understand the interplay between
hypoxia, HIF-1a and adenosine in skin fibrosis.
A schema for the involvement of the described path-
ways in promoting the profibrotic effects of A2A recep-
tor activation is provided in Figure 6. Taken together,
these data suggest that the A2A receptor-mediated
increase in collagen type I is, at least in part, mediated
by Fli1 down-regulation and therefore CTGF and col-
lagen gene derepression. Thus, the adenosine A2A recep-
tor-mediated loss of inhibition of dermal matrix protein
synthesis through regulation of Fli1, and the resultant
increase in the production of matrix and profibrogenic
growth factors such as CTGF, is likely a contributor to
the pathogenesis of skin thickening in scleroderma.
Conclusions
In summary, the results of our present work confirm
previous observations of the role of the adenosine A2A
receptor in the pathogenesis of dermal fibrosis in condi-
tions such as scleroderma by promoting the production
of tissue matrix and profibrotic mediators. These studies
suggest new mechanisms for the profibrogenic effects of
the A2A receptor by suppressing Fli1 expression and
increasing CTGF secretion. Such mechanisms may play
a role in matrix production in other fibrosing diseases,
such as cirrhosis, and these mechanistic targets may be
further explored as potential anti-fibrotic therapies.
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